ERBB2 and breast cancer: Several studies have clinically established TILs as a robust prognostic biomarker in triple-negative breast cancer (TNBC) and Her2+ breast cancer [42,47,48,49,50,51,52], which endorse the need to incorporate TILs as part of standard clinical histopathologic examination of TNBC [53,54,55,56].